MISTR Labs: What Gets Tested, How It Works, and What It Costs

If you're researching MISTR, the lab process is probably where your questions actually are. "Free PrEP" is easy to say; what people want to know is whether they have to go somewhere, what gets tested, whether a needle is involved, and how long it takes.

Here's the whole thing.

Why PrEP requires labs at all

Testing isn't a formality bolted on to make telehealth look legitimate. It's clinically load-bearing, for three reasons:

• You must be HIV-negative to start PrEP. This is the critical one. PrEP medications are two of the drugs used in HIV treatment, but two drugs alone are not adequate treatment for an established infection. Starting PrEP with an undiagnosed acute HIV infection can drive drug resistance and compromise your future treatment options. This is why every legitimate provider tests first and why grey-market PrEP is dangerous.
• Tenofovir disoproxil affects kidney function in a small minority of people. Baseline and ongoing creatinine testing catches that early, when it's reversible.
• Hepatitis B status changes the plan. Both PrEP drugs are active against hepatitis B. If you have chronic hep B and stop PrEP abruptly, you can experience a serious flare. Knowing your status up front prevents that.

Bacterial STI screening isn't strictly required to dispense PrEP, but the CDC recommends it at the same intervals, and it's arguably the single most useful thing in the panel — because most of these infections have no symptoms.

What's on the panel

This is a stronger panel than some competing telehealth services offer, and considerably stronger than a walk-in "STD test" that checks urine only.

Why three-site testing matters

This is the detail that separates adequate screening from a false sense of security.

A large proportion of gonorrhea and chlamydia infections among men who have sex with men are pharyngeal (throat) or rectal rather than urethral. A urine-only test misses them entirely. You get a clean result, you feel reassured, and the infection continues untreated — asymptomatic, transmissible, and in the case of untreated infections, contributing to onward spread.

Three-site collection means swabs from throat and rectum in addition to a urine sample. The swabs are self-collected, which people generally find far less awkward than the clinic version. If a provider's STI screening doesn't specify three-site, ask.

At-home kit vs. in-person collection

Neither option is "better" clinically. The at-home kit adds a few days for shipping in each direction; the in-person option is faster but requires leaving the house. Both use certified labs and both feed results into your MISTR dashboard.

The timeline, start to medication

What happens if a result is positive

Reasonable thing to worry about. Here's the actual handling:

• HIV positive. You will not be prescribed PrEP — that would be clinically harmful. MISTR provides long-term HIV care and antiretroviral therapy, so it can transition you into treatment rather than leaving you to find care yourself. A reactive screening result also requires confirmatory testing; an initial reactive result is not a diagnosis on its own.
• Bacterial STI positive. Chlamydia and syphilis are treatable and the provider handles the prescription. Gonorrhea is the exception worth knowing about: current treatment is an intramuscular ceftriaxone injection, which cannot be given through telehealth. You'll be directed to an in-person clinic for that specific one.
• Hepatitis B positive. Changes your PrEP plan and requires follow-up, but doesn't necessarily rule out PrEP — it means you shouldn't stop abruptly.
• Abnormal kidney function. May push the prescriber toward Descovy rather than tenofovir disoproxil-based PrEP, or toward closer monitoring.

Ongoing testing every three months

PrEP is not a one-time prescription. Renewal requires repeat HIV testing roughly every three months, along with kidney function and STI screening. MISTR builds this into the service — the three-site chlamydia and gonorrhea testing is part of the required quarterly labs.

This quarterly rhythm is genuinely one of the strongest public health arguments for PrEP beyond HIV prevention itself: it pulls a population that often avoids clinical care into regular comprehensive STI screening. A meaningful share of asymptomatic infections get caught this way that otherwise wouldn't be.

What the labs cost you

For most patients, nothing.

MISTR's model covers labs, consultations, and prescriptions for both insured and uninsured patients, working with a network of 340B-certified community nonprofit organizations. For insured patients, the labs are billed as preventive services — and federal rules require plans to cover PrEP ancillary services including HIV testing, hepatitis screening, kidney function testing, and STI screening with no cost sharing. For uninsured patients, the 340B arrangement and patient assistance programs cover it.

For comparison: paid entirely out of pocket at a commercial lab, that quarterly panel typically runs somewhere between $150 and $400, plus a clinic visit fee. Over a year of quarterly monitoring, the testing is often worth more than the medication. It's the least visible and most valuable part of the service.

We break down the full economics in our MISTR review, including how the 340B model actually works and what the catch is.

Privacy and who sees your results

Results go to your MISTR dashboard. The service is HIPAA-compliant and packaging is discreet — neither the lab kit nor the medication shipment identifies its contents externally.

The genuine privacy gap is insurance. If MISTR bills your insurance and you're a dependent on someone else's policy, an Explanation of Benefits goes to the policyholder. If that's a problem for you, say so during intake — the uninsured/patient-assistance pathway exists precisely for people in this situation, and it doesn't generate an EOB. Several state programs are also built for people who have insurance but can't safely use it.

Frequently asked questions